News: Simtuzumab

We provide the latest news and info on Simtuzumab

Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A ...
Seeking Alpha (registration)
GILD anticipates to release during the 4Q14 (most likely at ASH December 08th 2014) the first simtuzumab (LOXL2 mAb) data in oncology in combination with Jakafi in Myelofibrosis. We support UBS estimates that these Phase 2 indications are worth ~$3B, ...

Published on Monday 15th of September 2014 03:48:20 PM Read more...

Gilead Sciences' (GILD) President John Milligan Presents at the 2014 Robert W ...
Seeking Alpha (registration)
and then finally, we're branching into biologics. we have two antibodies in development now, one called Simtuzumab, which is for the treatment of – or potential treatment of fibrotic diseases. It may also enhance the ability of chemotherapeutic agents ...

and more »

Published on Monday 15th of September 2014 03:48:20 PM Read more...

Gilead Update: Good News Keeps On Coming; Much Higher Share Prices ...
Seeking Alpha (registration)
Both simtuzumab and momelitinib are in trials for treatment of both myelofibrosis and pancreatic cancer, two quite different diseases. Two approaches to treating hepatitis B are under development. As stated, idelalisib (Zydelig) and GS-9973, a SYK ...

and more »

Published on Monday 15th of September 2014 03:48:20 PM Read more...

UBS Remains Bullish on Biotech; Achillion Pharma (ACHN) PT Raised to $15 ...
StreetInsider.com (subscription)
[2] We also think multiple expansion can be driven by pipeline catalysts this fall, including CELG's GED-301, initial data for GILD's simtuzumab in cancer (where expectations are non-existent, in our view), and 7-day data for ACHN's nuc in HCV. [3] We ...

Published on Monday 15th of September 2014 03:48:20 PM Read more...

No, the Biotech Rally Isn't Over
Barron's (blog)
[2] We also think multiple expansion can be driven by pipeline catalysts this fall, including Celgene's GED-301, initial data for Gilead Sciences' simtuzumab in cancer (where expectations are non-existent, in our view), and 7-day data for Achillion ...

and more »

Published on Monday 15th of September 2014 03:48:20 PM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts